Search
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma
Montmorillonite
go.drugbank.com/drugs/DB13654InvestigationalCategories: Compounds used in a research, industrial, or household settingProducts: SmectaGo 3g Oral Suspension In SachetMetildigoxin
go.drugbank.com/drugs/DB13401InvestigationalCategories: Compounds used in a research, industrial, or household settingSodium apolate
go.drugbank.com/drugs/DB13477ExperimentalCategories: Compounds used in a research, industrial, or household settingBetadex
go.drugbank.com/drugs/DB03995InvestigationalCategories: Compounds used in a research, industrial, or household settingNorelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin was first approved in the United States in 2001 as the progestin in a norelgestromin and ethinyl estradiol transdermal contraceptive system.[L63816] … It is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.
Moschus berezovskii musk sac resin
go.drugbank.com/drugs/DB14247InvestigationalMoschus berezovskii musk sac resin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Livoletide
go.drugbank.com/drugs/DB15188InvestigationalLivoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).
Bixalomer
go.drugbank.com/drugs/DB15200InvestigationalBixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Gotistobart
go.drugbank.com/drugs/DB19100InvestigationalGotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).